Edoxaban in venous thromboembolism and stroke prevention: an appraisal

Figures & data

Table 1 Edoxaban summary

Route of administration	Oral
Onset of action	Rapid
Bioavailability	62%
Development name	DU-176b
IUPAC name	N-(5-chloropyridin-2-yl)-N′-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)-cyclohexyl]ethanediamide p-toluenesulfonate monohydrate
Major indications	NVAF, VTE, major orthopedic surgery (only in Japan)
Pharmacology description	Factor Xa inhibitor
Approval route	Approved in the USA, Europe, and Japan

Abbreviations: IUPAC, International Union of Pure and Applied Chemistry; NVAF, nonvalvular atrial fibrillation; VTE, venous thromboembolism.

Table 2 Phase III randomized clinical trials evaluating edoxaban efficacy and safety

Study	Year	Study groups	Patients	Mean FU	Primary outcome
ENGAGE AF-TIMI 48^Citation20	2009	Edoxaban 60 mg OD	7,035	2.8 years	Stroke/SEE
		Edoxaban 30 mg OD	7,034
		Dose-adjusted warfarin (INR 2–3)	7,036
Hokusai-VTE^Citation46	2013	Edoxaban 60 mg OD	4,118	8.2 months	Recurrent symptomatic VTE
		Dose-adjusted warfarin (INR 2–3)	4,122

Abbreviations: FU, follow-up; INR, international normalized ratio; OD, once daily; SEE, systemic embolic event; VTE, venous thromboembolism.

GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359

 PubMed Web of Science ®Google Scholar

BüllerHRDécoususHGrossoMAEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med2013369151406141523991658

 PubMed Web of Science ®Google Scholar